EUCTR2007-002470-59-GB进行中（未招募）不适用
AN OPEN LABEL CONTINUATION STUDY OF THE EFFECTS OF MTC 30 MG TID AND 60 MG TID IN PATIENTS WITH ALZHEIMER’S DISEASE - Open Label Study of Methylthioninium Chloride (MTC) in Alzheimer’s Disease
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for the study all of the following criteria must be fulfilled:
- •1. The patient may be of either sex and must be supervised by a carer who is competent to ensure compliance with the medication and who is willing to participate in completing the various assessments. The carer must provide written consent to his or her own participation in the study.
- •2. Patients with capacity must give written informed consent to participate in this study. Patients who lack capacity to consent must be in agreement with entering into the study and have a personal legal representative giving written informed consent to their participation.
- •3. The patient must have been ongoing in TRx-014-001 at time of study termination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •There are no exclusion criteria. All patients taking medication at the termination of study TRx-014-001 and who wish to participate are eligible for recruitment.
研究者
相似试验
进行中（未招募）
不适用
An open label, exploratory study on the effect of rhBSSL on the fat absorption in patients with cystic fibrosis and pancreatic insufficiency. - N/AEUCTR2007-004063-21-NLBiovitrum AB18
进行中（未招募）
1 期
An Open Label, Longitudinal Study of the Effects of Subcutaneous Acute and Chronic Pasireotide (SOM230) Therapy on Adrenocorticotrophic Hormone and Tumour Volume in Patients with Nelson's Syndrome. - Pasireotide Therapy in Patients with Nelson's Syndrome Version 1.1elson's SyndromeEUCTR2009-014457-33-GBSheffield Teaching Hospitals NHS Foundation Trust8
尚未招募
4 期
AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM ENCORAFENIB/BINIMETINIB CLINICAL STUDIESocally advanced unresectable or metastatic melanoma with BRAFV600 mutation and previously untreatedJPRN-jRCT2041220160Oki Kosuke3
进行中（未招募）
1 期
An open-label extension study evaluating the safety and tolerability of leuco-methylthioninium dihydromesylate (LMTM) in subjects with Alzheimer's Disease or a rare form of dementia (Behavioral Variant Frontotemporal Dementia) who have completed an earlier Phase trialAlzheimer’s Disease and behavioral variant Frontotemporal DementiaMedDRA version: 19.0Level: PTClassification code 10068968Term: Frontotemporal dementiaSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 19.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-002013-37-NLTauRx Therapeutics Ltd966
进行中（未招募）
1 期
An open-label extension study evaluating the safety and tolerability of leuco-methylthioninium dihydromesylate (LMTM) in subjects with Alzheimer's Disease or a rare form of dementia (Behavioral Variant Frontotemporal Dementia) who have completed an earlier Phase trialAlzheimer’s Disease and behavioral variant Frontotemporal DementiaMedDRA version: 19.0 Level: PT Classification code 10068968 Term: Frontotemporal dementia System Organ Class: 10029205 - Nervous system disordersMedDRA version: 19.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disordersEUCTR2014-002013-37-GBTauRx Therapeutics Ltd966